BRPI0607827B8 - composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso - Google Patents

composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso

Info

Publication number
BRPI0607827B8
BRPI0607827B8 BRPI0607827A BRPI0607827A BRPI0607827B8 BR PI0607827 B8 BRPI0607827 B8 BR PI0607827B8 BR PI0607827 A BRPI0607827 A BR PI0607827A BR PI0607827 A BRPI0607827 A BR PI0607827A BR PI0607827 B8 BRPI0607827 B8 BR PI0607827B8
Authority
BR
Brazil
Prior art keywords
compound
production
protease inhibitor
inhibitor precursor
precursor compound
Prior art date
Application number
BRPI0607827A
Other languages
English (en)
Inventor
Linclau Bruno
Original Assignee
Janssen R & D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R & D Ireland
Publication of BRPI0607827A2 publication Critical patent/BRPI0607827A2/pt
Publication of BRPI0607827B1 publication Critical patent/BRPI0607827B1/pt
Publication of BRPI0607827B8 publication Critical patent/BRPI0607827B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso. a presente invenção refere-se a um composto tendo a estrutura (i), e processos para a produção deste, e os intermediários usados em tal processo.
BRPI0607827A 2005-02-25 2006-02-24 composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso BRPI0607827B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101462 2005-02-25
US68369905P 2005-05-23 2005-05-23
PCT/EP2006/060246 WO2006089942A1 (en) 2005-02-25 2006-02-24 Protease inhibitor precursor synthesis

Publications (3)

Publication Number Publication Date
BRPI0607827A2 BRPI0607827A2 (pt) 2009-10-06
BRPI0607827B1 BRPI0607827B1 (pt) 2019-11-05
BRPI0607827B8 true BRPI0607827B8 (pt) 2021-05-25

Family

ID=36646227

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607827A BRPI0607827B8 (pt) 2005-02-25 2006-02-24 composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso

Country Status (19)

Country Link
US (2) US8067463B2 (pt)
EP (1) EP1856125B1 (pt)
JP (1) JP5260965B2 (pt)
KR (1) KR101333627B1 (pt)
CN (1) CN101128469B (pt)
AT (1) ATE440848T1 (pt)
AU (1) AU2006217922B2 (pt)
BR (1) BRPI0607827B8 (pt)
CA (1) CA2595295C (pt)
DE (1) DE602006008751D1 (pt)
DK (1) DK1856125T3 (pt)
ES (1) ES2331257T3 (pt)
IL (1) IL184519A (pt)
MX (1) MX2007010378A (pt)
NO (1) NO20074880L (pt)
PL (1) PL1856125T3 (pt)
PT (1) PT1856125E (pt)
RU (1) RU2421459C2 (pt)
WO (1) WO2006089942A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5288153B2 (ja) * 2007-03-30 2013-09-11 日油株式会社 糖アルコール誘導体およびアルケニル基含有糖アルコール誘導体の製造方法
US8802724B2 (en) * 2010-11-30 2014-08-12 Purdue Research Foundation Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans
CN116102569A (zh) * 2021-11-11 2023-05-12 深圳容金科技有限公司 一种展青霉素半抗原的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
DK1088098T4 (en) 1998-06-23 2015-09-14 Us Of America Represented By The Secretary Dept Of Health And Human Services Fitnessassay and methods for reducing HIV resistance to therapy
EP1089328A1 (en) * 1999-09-29 2001-04-04 Infineon Technologies AG Method for manufacturing of a semiconductor device
CN1191256C (zh) 1999-10-06 2005-03-02 泰博特克药品有限公司 作为逆转录病毒蛋白酶抑制剂的六氢呋喃并[2,3－b]呋喃－3－基－N－{3－[(1,3－苯并二氧杂环戊－5－基磺酰基)(异丁基)氨基)－1苄基－2－羟丙基}氨基甲酸酯
ATE343567T1 (de) 2001-02-14 2006-11-15 Tibotec Pharm Ltd Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren
PL367084A1 (en) 2001-04-09 2005-02-21 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
AU2002310818B2 (en) 2001-05-11 2007-12-13 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors
EP1265073A3 (en) 2001-06-05 2003-11-26 Tibotec Pharmaceuticals Ltd. Methods for determining plasma free drug concentration
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
HUP0500164A3 (en) 2001-12-21 2009-03-30 Tibotec Pharm Ltd Heterocyclic substituted benzenesulfonamides as hiv protease inhibitors and pharmaceutical compositions containing them
WO2003064406A1 (en) 2002-01-07 2003-08-07 Sequoia Pharmaceuticals Resistance-repellent retroviral protease inhibitors
CA2474671A1 (en) 2002-02-22 2003-08-28 Tibotec Bvba Methods for determining the influence of protein binding on antiretroviral activity
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003231766A1 (en) 2002-04-26 2003-11-10 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
LT2767539T (lt) 2002-05-16 2017-09-25 Janssen Sciences Ireland Uc Pseudopolimorfinės živ proteazės inhibitorių formos
PL373425A1 (en) 2002-05-17 2005-08-22 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
DE60327768D1 (de) 2002-07-01 2009-07-09 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease

Also Published As

Publication number Publication date
CA2595295C (en) 2014-07-08
ES2331257T3 (es) 2009-12-28
DK1856125T3 (da) 2009-12-07
IL184519A0 (en) 2007-10-31
WO2006089942A8 (en) 2007-12-13
PL1856125T3 (pl) 2010-01-29
BRPI0607827B1 (pt) 2019-11-05
EP1856125A1 (en) 2007-11-21
AU2006217922A1 (en) 2006-08-31
US20090054668A1 (en) 2009-02-26
WO2006089942A1 (en) 2006-08-31
US8067463B2 (en) 2011-11-29
CN101128469A (zh) 2008-02-20
ATE440848T1 (de) 2009-09-15
CA2595295A1 (en) 2006-08-31
NO20074880L (no) 2007-09-25
JP5260965B2 (ja) 2013-08-14
BRPI0607827A2 (pt) 2009-10-06
RU2007135345A (ru) 2009-03-27
US8183394B2 (en) 2012-05-22
DE602006008751D1 (de) 2009-10-08
US20120041215A1 (en) 2012-02-16
IL184519A (en) 2012-01-31
JP2008531522A (ja) 2008-08-14
KR101333627B1 (ko) 2013-11-27
CN101128469B (zh) 2012-11-14
PT1856125E (pt) 2009-11-06
AU2006217922B2 (en) 2012-04-05
MX2007010378A (es) 2007-09-25
KR20080005183A (ko) 2008-01-10
RU2421459C2 (ru) 2011-06-20
EP1856125B1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
CY1114916T1 (el) Μεθοδοι
BRPI0606961A2 (pt) sistema de usinagem rápida e métodos para fabricação de artigos abrasivos
UY29479A1 (es) Inhibidores de adn-pk
CR7970S (es) Botella
BRPI0519710A2 (pt) aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio
BRPI0500395B8 (pt) processo para a síntese de (7-metóxi-1-naftil)acetonitrila e sua aplicação na síntese de agomelatina
PA8804601A1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios.
BRPI0710199A2 (pt) Processo para preparação de inibidores de hiv protease
UY30488A1 (es) Bencilaminas,un proceso para su produccion y su uso como agentes anti-inflamatorios.
BRPI0608137A2 (pt) processo de epoxidação de olefina, catalisador para uso no processo, carreador para uso na fabricação de catalisador, e processo para fabricar o carreador
BRPI0515186A (pt) derivados de alquilideno-tetrahidronaftaleno, processo para a sua produção e seu uso como antiinflamatório
ATE429417T1 (de) Hiv-protease-inhibitoren
UY30185A1 (es) Método para la producción preferencial de isómeros geométricos y método de aislamiento
BRPI0607827B8 (pt) composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso
NI200700175A (es) Procesos para la preparación de alcoholes de aminoetoxibencilo
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
BRPI0513778A (pt) processo para a preparação de compostos, e, uso dos compostos
BR0314592A (pt) Processo para preparação de intermediários
UA94391C2 (ru) Синтез предшественника ингибитора протеазы
WO2006116687A3 (en) Nanoassays
BRPI0612676A2 (pt) processo para preparar compostos, compostos, e, uso de compostos
TW200738731A (en) Substituted aminophenylsulfonamide compounds and derivatives as HIV protease inhibitor

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.